Company intelligence / Profile preview

Axxess

Singapore

Ownership: Private
Development stage: Other

Overview

As of November 2023, AxxessBio has exclusive distribution rights for Translarna™ (ataluren, for DMD) in Southeast Asia and a service agreement for Upstaza™ (eladocagene exuparvovec, for AADC Deficiency).

Therapeutic areas: Rare Diseases
Modalities: Small moleculeGene therapy
Industry: Biotech

Partnerships

PTC Therapeutics International Limited (exclusive Southeast Asia distribution for Translarna™ and service agreement for Upstaza™)

Beyond the preview

Go deeper on Axxess.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Axxess.

Explore the full profile